Alpine Immune Sciences Inc (NASDAQ:ALPN) was the recipient of a significant decline in short interest in September. As of September 30th, there was short interest totalling 17,000 shares, a decline of 29.8% from the August 30th total of 24,200 shares. Based on an average daily volume of 14,400 shares, the short-interest ratio is currently 1.2 days. Approximately 0.2% of the company’s stock are short sold.
ALPN stock traded up $0.20 during trading hours on Friday, hitting $2.91. The company’s stock had a trading volume of 25,633 shares, compared to its average volume of 13,394. The company has a quick ratio of 4.56, a current ratio of 4.56 and a debt-to-equity ratio of 0.27. The company has a market capitalization of $54.04 million, a PE ratio of -1.11 and a beta of 1.85. Alpine Immune Sciences has a 12 month low of $2.68 and a 12 month high of $8.24. The stock has a 50 day moving average price of $4.18 and a two-hundred day moving average price of $5.01.
Alpine Immune Sciences (NASDAQ:ALPN) last posted its earnings results on Tuesday, August 13th. The biotechnology company reported ($0.64) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.68) by $0.04. The business had revenue of $0.57 million during the quarter, compared to the consensus estimate of $0.25 million. Sell-side analysts expect that Alpine Immune Sciences will post -2.67 earnings per share for the current year.
A number of brokerages recently commented on ALPN. Zacks Investment Research downgraded shares of Alpine Immune Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday, August 21st. ValuEngine raised shares of Alpine Immune Sciences from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st.
Hedge funds have recently bought and sold shares of the business. Leonard Rickey Investment Advisors P.L.L.C. bought a new stake in Alpine Immune Sciences in the second quarter worth approximately $42,000. Jacobs Levy Equity Management Inc. bought a new stake in Alpine Immune Sciences in the second quarter worth approximately $90,000. Renaissance Technologies LLC grew its position in Alpine Immune Sciences by 10.8% in the second quarter. Renaissance Technologies LLC now owns 106,261 shares of the biotechnology company’s stock worth $447,000 after acquiring an additional 10,400 shares in the last quarter. Finally, Vanguard Group Inc. grew its position in Alpine Immune Sciences by 67.7% in the second quarter. Vanguard Group Inc. now owns 202,582 shares of the biotechnology company’s stock worth $853,000 after acquiring an additional 81,800 shares in the last quarter. 46.91% of the stock is owned by institutional investors.
Alpine Immune Sciences Company Profile
Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202, a programmed cell death protein ligand 1 (PD-L1)/cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antagonist with PD-L1 dependent CD28 costimulation for the treatment of cancer.
Featured Story: What are catch-up contributions?
Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.